Inactive Instrument

Highlights HLS Therapeutics Inc Toronto S.E.

Equities

AM

CA05328X1015

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	05-09	MT
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	05-09	MT
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	05-09	CI
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	04-08	CI
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	03-14	MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	03-14	MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	03-14	MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	03-14	CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	02-06	MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	02-06	MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo	11-14	MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	11-14	MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses	11-14	CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired.	11-12	CI
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	11-09	CI
HLS Therapeutics Inc. announces an Equity Buyback for 1,607,892 shares, representing 5% of its issued share capital.	11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights HLS Therapeutics Inc Toronto S.E.

Equities

AM

CA05328X1015

Highlights

Filters